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1. Introduction  
Pharmacokinetic (PK) characterization and in vivo pharmacological properties of new 
chemical entities are important components during lead compound selection and 
optimization in the drug discovery process. Accordingly, reliable techniques are needed that 
can generate the requisite pharmacokinetic/pharmacodynamic (PK/PD) information for an 
increased number of compounds. When dealing with compounds targeting the central 
nervous system (CNS), biophase PK may differ significantly from plasma PK, because 
blood-brain barrier (BBB) transport and brain distribution often do not occur 
instantaneously and to a full extent. Therefore the brain distributional behaviors are 
important determinants of in vivo drug effects. In vivo microdialysis technique has been used 
increasingly over the past years for in vivo sampling of extracellular exogenous compounds 
in brains of freely moving rats (1-3). The extracellular brain concentration of free drug which 
measured by microdialysis may reflect the amount of drug available at the pharmacological 
target. As the microdialysis technique also allows the simultaneous determination of 
different endogenous substances, such as neurotransmitters, which sometimes represent the 
efficacy biomarker of a CNS drug, in the same local interstitial environment. Microdialysis is 
an attractive tool for PK/PD investigations of CNS active drugs (4). However, the 
extracellular concentration of neurotransmitters in the synaptic cleft is very low which can 
be in the range of fg/µl; the sampling recovery of microdialysis probe is less than 20%. The 
application of this technique was highly limited by lack the proper sensitive analytical 
methods to determine the endogenous substance and exogenous drug. 
For analysis of endogenous neurotransmitters, such as, serotonin (5-HT), dopamine (DA), 
noradrenaline (NE), acetylcholine (ACh), histamine, -aminobutyric acid (GABA) and 
glutamate (Glu), microdialysis in combination with high performance liquid 
chromatography (HPLC) - electrochemical detection (ED) or fluorescence detection has been 
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widely used in last two decades (5-6). 5-HT, DA and NE are electrochemically active and 
can be directly detected in electrochemical detector. However, histamine, Glu and GABA 
need a pre-column derivatization to produce electrochemical or fluorescence derivatives for 
their measurement (7-10).  The sensitivity of this latter method is further limited by the 
instability of the final derivatives and the yield of derivatizations. ACh in microdialysate are 
measured by HPLC-ED following a post-column enzyme reactor and frequently below the 
detection limit (11). Most investigators have used acetylcholinesterase inhibitors in the 
perfusion medium to increase basal extracellular ACh concentrations to readily detectable 
levels (12-13). However, the artificially increased concentration exerts a significant influence 
on the cholinergic system, thereby making interpretation of drug effects problematic (11, 14-
16). For analysis of exogenous drug, HPLC-ED was sensitive, but not applicable since most 
of drug candidates are electrochemically inactive.  
Liquid chromatography/tandem mass spectrometry (LC-MS/MS) technique improvement 
provides a direct, structural-specific measurement of individual components with very high 
sensitivity. The mass spectrometer has minimal baseline drift and can be equilibrated very 
rapidly. However, only a few LC-MS/MS methods for analysis of drugs and individual 
neurotransmitter in microdialysis sample have been reported (15-19) and analysis all 
neurotransmitters have never been reported. There are two major problems for the 
application (20). First, the critical requirement for the use of the LC-MS/MS systems is that 
the mobile phase must be volatile, because non-volatile ions could significantly reduce the 
ionization efficiency by ion suppression. The high ionic strength of microdialysis samples 
generates high background noise and suppresses the ionization of neurotransmitters 
resulting in considerable reductions in sensitivity and changes in peak shape. Second, these 
neurotransmitters are polar compounds with low molecular weights; their retentions on 
standard reversed phase column are generally poor. In the present study, we have used two 
approaches to solve these problems and developed a series of LC-MS/MS methods which 
enable us to monitor drug and all neurotransmitters, 5-HT, DA, NE, ACh, Histamine, 
GABA, Glu, in single microdialysis sample. The methods were applied to study donepezil, a 
selective acetylcholinesterase inhibitor for treatment of Alzheimer's disease; and citalopram, 
an antidepressant of selective serotonin reuptake inhibitor. These applications demonstrated 
in vivo microdialysis coupled with LC-MS/MS could 1). Examine the drug efficacy by 
measuring the changes of extracellular concentration of all neurotransmitters after acute 
systematic administration of a drug; 2). Estimate the BBB penetration of a drug by 
measuring the concentration of free drug in the brain interstitial fluid; 3). The time course of 
free drug in the targeted brain region provided a biophase PK information which was used 
to evaluate PK/PD relationship by comparing the time course of free drug versus 
biomarker.  
2. Methods 
2.1 In vivo microdialysis experiments 
Male Sprague Dawley rats (Charles River Laboratories, Wilmington, MA), weighing 300-400 
g and were single housed under standard laboratory conditions. Rats were implanted with a 
probe guide cannula (Eicom, Japan) at the prefrontal cortex (PFC) (21): Incisor bar, -3.5mm, 
A (anterior to bregma) 3.2 mm, L (lateral from the mid-sagittal suture) 0.8 mm, V (ventral to 
bregma) 1 mm. Microdialysis experiments were performed at least two days after surgery. 
Rats were placed in their home cages and connected to a dual channel microdialysis liquid 
swivel (Instech Solomon, Plymouth Meeting, PA, USA) mounted on a spring loaded counter 
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balanced arm which allowed animal freely moving. Microdialysis probes have a molecular 
weight cut-off of 50,000 Da. The exposed tubing of dialysis probe was 4 mm length with an 
outer diameter of 0.22 mm (Eicom, Japan). The input tube of the dialysis probe was 
connected to a CMA/102 Microdialysis Pump (CMA, Sweden), which delivered an artificial 
cerebrospinal fluid (aCSF) containing 147 mM NaCl, 4 mM KCl, 0.85 mM MgCl2, 2.3 mM 
CaCl2. The probe was perfused with aCSF at a rate of 0.6 μl/min overnight to obtain the 
stable basal level of neurotransmitters. The following morning the flow rate was increased 
to 1.0 μl/min and microdialysis samples were collected every 60 min to a 96 well plate, 
starting from 8:00 am for 20 hours.  New probes were used every time without determining 
in vitro recovery. Fifteen μl antioxidant which contained 3 mM L-cysteine and 1 mM oxalic 
acid in 0.1 M acetic acid was added to each sample to prevent serotonin oxidation.  
Donapazil (2 mg/kg s.c.) or citalopram (10 mg/kg s.c.) were administrated to animal after 
four baseline microdialysis samples were obtained. The 60 l microdialysis sample plus 15 
μl antioxidant can be aliquot to each 5 l, then diluted to 50 l. Ten μl was used for each LC-
MS/MS injection.  Five to six rats were used for each treatment group. Vehicle animals 
received 5% N-methyl-2-pyrrolidone solution (v/v, 1 ml/kg, s.c.) injection. The drug 
concentration in the microdialysis samples were calculated by using in vitro recovery of 
microdialysis probe at a perfusion rate of 1.0 l/min.  
2.2 LC-MS/MS methods 
The LC-MS/MS system consisted of two Shimadzu LC-10AD pumps (Shimadzu, Kyoto, 
Japan) coupled to an Applied Biosystems API-4000TM triple-quadrupole mass spectrometer 
equipped with a TURBO VTM Ion Source (Applied Biosystems/MDS SCIEX, Toronto, 
Canada). A CTC Analytics HTS PAL autosampler (Leap Technologies, Carrboro, NC, USA) 
fitted with a cooled sample tray and a six-port injection valve with a 20 l injection loop. A 
ten-port diverter valve was equipped between column and mass spectrometer to divert salt 
to waste.  The mass spectrometer was operated in electrospray positive ion mode and 
monitored with multiple reaction monitoring (MRM) using the parameters described in 
Table 1. Data was acquired using Analyst® software (version 1.4.1).  The mass spectrometric 
(ion path) conditions for neurotransmitters and drugs were determined by using the 
quantitative optimization function of Analyst® software. Different HPLC Methods were 
developed for each neurotransmitter and drug. 
2.2.1 ACh, 5-HT and DA method 
100 mm x 2.1 mm i.d., 3 m, Dicovery HS F5 column (Supelco, Bellefonte, PA, USA). Mobile 
Phase A and B were composed of formic acid (0.1%, v/v) in water and acetronitrile, 
respectively. An elution profile was composed of an isocratic step of 100% A for 1.5 min and 
then a linear gradient to 90% B over 3.5 min to separate DA, 5-HT and ACh, kept at 90% B 
for 1.5 min then equilibrated with 100% A for 1 min. The flow rate was 0.5 ml/min. Valco 
valve was diverted to MS from 2.5 to 5 min.  
2.2.2 Histamine method 
100 mm x 2.1 mm i.d., 3 m, Dicovery HS F5 column (Supelco, Bellefonte, PA, USA). Mobile 
Phase A and B were composed of formic acid (0.05%, v/v) in water and acetronitrile, 
respectively. An elution profile was composed of an isocratic step of 95% B for 2.0 min and 
then a linear gradient to 5% B over 0.5 min to let salts elute first, held at 5% B for 4.0 min, 
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Analyate 
 
DA 5-HT NA ACh Histemine GABA Glu Donepezil Citalopram 
 
Transition 
(m/z) 
 
154137
 
177160
 
170152
 
14660
 
11295 
 
10487
 
14884
 
380243 
 
325109 
Declustering 
potential 
(DP, V) 
 
41 
 
36 
 
31 
 
41 
 
41 
 
21 
 
36 
 
81 
 
76 
Collision cell 
entrance 
potential 
(CE, V) 
 
15 
 
16 
 
13 
 
17 
 
21 
 
15 
 
23 
 
37 
 
39 
Collision cell 
exit 
potential 
(CXP, V) 
 
10 
 
11 
 
12 
 
4 
 
8 
 
6 
 
6 
 
22 
 
8 
Entrance 
potential 
(EP) 
 
10 
 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
Collision gas 
ion energy 
(CAD) 
 
6 
 
6 
 
5 
 
6 
 
5 
 
5 
 
5 
 
5 
 
5 
Curtain gas 
(CUR) 
 
14 
 
14 
 
15 
 
14 
 
15 
 
 
15 
 
15 
 
15 
 
15 
Ion Source 
Gas 1 (GS1) 
 
55 
 
55 
 
50 
 
55 
 
50 
 
 
50 
 
50 
 
50 
 
50 
IonSpray 
Voltage 
(GS2) 
 
50 
 
50 
 
50 
 
50 
 
50 
 
50 
 
50 
 
50 
 
50 
IonSpray 
Voltage (IS) 
 
3000 
 
3000 
 
3000 
 
3000 
 
3000 
 
 
3000 
 
3000 
 
3000 
 
3000 
Temperature 
(TEM) 
 
500 
 
500 
 
500 
 
500 
 
650 
 
 
500 
 
650 
 
600 
 
600 
 
Table 1. The system parameters of mass spectrometry. 
then equilibrated with 95% B for 1.5 min. The flow rate was 0.5 ml/min. Valco valve was 
diverted to MS from 3.8 to 5 min. 
2.2.3 Glu method 
150 mm x 4 mm i.d., 3 m, Dicovery HS F5 column (Supelco, Bellefonte, PA, USA). Mobile 
Phase A and B were composed of formic acid (0.05%, v/v) in water and acetronitrile, 
respectively. An elution profile was composed of an isocratic step of 100% A for 1.5 min and 
then a linear gradient to 95% B over 0.5 min, held at 95% B for 1.0 min then equilibrated 
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with 100% A for 3.5 min. The flow rate was 1.2 ml/min. Valco valve was diverted to MS 
from 1.3 to 2 min.  
2.2.4 GABA and NE method 
50 mm x 2.1 mm i.d., 5 m, 100 Å Primesep 200 column (SIELC Technologies, Prospect 
Heights, IL, USA). Mobile Phase A and B were composed of acetic acid (0.2%, v/v) in water 
and acetronitrile, respectively. An elution profile composed of an isocratic step of 90% A for 
1.5 min and then a linear gradient to 90% B over 3.5 min for separation, hold at 90% B for 1.5 
min then equilibrate with 100% A for 1 min. The flow rate was 0.5 ml/min. Valco valve was 
diverted to MS from 2.5 to 5 min.  
2.2.5 Donepezil and citalopram method 
30 mm x 2.0 mm i.d., Synergi 4 Hydro-RP 80 Å column (Phenomenex. Torrance, CA, USA). 
Mobile Phase A and B were composed of formic acid (0.05%, v/v) in water and acetronitrile, 
respectively. An elution profile was composed of an isocratic step of 90% A for 1.5 min and 
then a linear gradient to 90% B over 3.5 min for separation, held at 90% B for 1.5 min then 
equilibrated with 100% A for 1 min. The flow rate was 0.5 ml/min. Valco valve was diverted 
to MS from 2.5 to 5 min.  
2.3 Analysis of extracellular 5-HT and NE levels by HPLC-ED  
Compared to LC-MS/MS method, 5-HT and NE are easier to measure by high-performance 
liquid chromatography (ESA Model 582) coupled to an electrochemical detector (CoulArray 
Coulometric, ESA) with dual channel coulometric microdialysis cell (ESA 5014B). Separation 
was performed on a C18 column (Hypersil, 150 x 3.2 mm I.D.) at room temperature.  The 
mobile phase consisted of 75 mM NaH2PO4, 0.5 mM Disodium-EDTA, 350 mg/L 1-
octanesulfonic acid, pH 3.1, 1.0% THF, 9.0% ACN.  The flow rate was 0.4 ml/min. 22μl 
microdialysate was injected by an autosampler (ESA Model 540).  The first electrode of the 
detector was set at –90 mV (reduction) and the second at +280 mV (oxidation). 
2.4 Statistical analysis 
All values for microdialysis studies were calculated as percentage change at each time point 
compared with the average of four baseline values. The extracellular neurotransmitter 
concentration at each time point after vehicle injection was compared with the average of 
four baseline values by one way ANOVA - Dunnett’s test for their significant differences.   
The overall effect of drug treatments on extracellular neurotransmitter levels was 
determined by a two way ANOVA with treatment as the independent variable and time as 
the repeated measurement. If significant, the ANOVA was followed by post-hoc Duncan’s 
multiple range test (SigmaStat,  SPSS Inc., www.spss.com).  
3. Results 
Figure 1 shows the mass spectra and molecular structures of precursor ions and associated 
daughter ions of neurotransmitters, donepezil and citalopram.  The spectra show several 
prominent fragment ions. The ion that was selected for the detection of each 
neurotransmitter and drug was always the highest intensity ion except ACh. For ACh the 
lower intensity ion at m/z = 60 gave greater signal to noise than the higher intensity 
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product ion at m/z = 86. A summary of MRM parameters for all positive mode analytes was 
given in table 1.  
Figure 2 shows the representative chromatogram of each neurotransmitter and drug in 
standard mixture solution (1 pg/μl standard in 1:10 dilution of aCSF) and in 1:10 dilution of 
basal level microdialysates from frontal cortex of freely moving rat.   
3.1 Drug effect on the extracellular neurotransmitters levels in rat frontal cortex 
The LC-MS/MS methods were applied to evaluate the effects of acute administration of 
either donepezil or citalopram on the extracellular concentration of ACh, Histamine, GABA,  
Glu, DA, NE and 5-HT in rat frontal cortex (as shown in Figure 3).  Before dosing the 
animal, four 60 l microdialysis samples were collected and the basal extracellular 
concentration of neurotransmitters in rat frontal cortex which were measured by LC-
MS/MS methods are (mean  S.E.): ACh, 1.93  0.14 pg/l (n=15); Histamine, 1.2  0.15 
pg/l  (n=15); GABA, 6.25  0.35 pg/l (n=15); Glu, 2.44  0.25 ng/l (n=15); DA, 0.15  
0.008 pg/l (n=15); NE, 0.40  0.015 pg/l (n=8) and 5-HT, 0.20  0.016 pg/l (n=6). Since 
the LC-MS/MS methods presented here required a 10-fold dilution of the microdialysis 
sample, the 5-HT and NE detection limit was challenging and the HPLC-ED was a preferred 
method for these analytes. The basal extracellular concentrations of 5-HT and NE (Mean  
S.E.) in frontal cortex which measured by HPLC-ED were NE: 0.36 ± 0.15 pg/ml (n=20) and 
5-HT, 0.10  0.06 pg/l (n=50).  
Vehicle administration (n=5) did not significantly alter basal extracellular ACh, Histamine, 
GABA, Glu, DA, NE and 5-HT concentration in rat frontal cortex as shown in Figure 3.  The 
acute administration of donepezil (2.0 mg/kg, s.c., n=5) evoked a significant increase of 
extracellular ACh from basal levels in the frontal cortex of rats compared with vehicle 
animal, to a maximum of 645  69% at the first hours post dose and the average over the 3-6 
hour treatment period was sustained at 178  12% of basal values (as shown in Figure 3A). 
Donepezil did not significantly change the extracellular concentration of Histamine, GABA, 
DA, NE and 5-HT (Figure 3B, 3C, 3E, 3F and 3G), but significantly decreased the Glu level in 
frontal cortex of rats compared with vehicle animal. Glu concentration continually 
decreased to a maximum of 57  17% at the sixth hour post dose (Figure 3D).   
The acute administration of citalopram (10 mg/kg, s.c., n=5) immediately evoked a 
significant increase of extracellular 5-HT from basal levels in the frontal cortex of rats 
compared to vehicle animals at the first hour post dose and the average over the 6 hour 
treatment period was sustained at 412  14% of basal values (as shown in Figure 3G). 
Citalopram did not significantly change the extracellular concentration of ACh, Histamine, 
Glu, DA and NE, (Figure 3A, 3B, 3D, 3E and 3F), but significantly decreased GABA level in 
frontal cortex of rats compared with vehicle animal. GABA level decreased to a maximum of 
53  9.4% at the forth hour post dose and the average over the 2-6 hour treatment period 
was sustained at 69%  4.6% of basal values (as shown in Figure 3C).  
3.2 Biophase PK profile and the PK/PD relationship  
The biophase PK profiles of donepezil and citalopram (as shown in Figure 4) were 
generated by measuring the extracellular concentration of free donepezil or citalopram in 
midialysate of rat frontal cortex using LC-MS/MS methods.  The PK profile was compared 
with the time course of extracellular concentration of neurotransmitters in the same 
microdialysate of frontal cortex to evaluate their PK/PD relationship (as shown in Figure 4). 
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Fig. 1. Part I 
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Fig. 1. Mass spectra and molecular structures of precursor ions and associated daughter ions 
for A). ACh; B). Histamine; C). GABA; D). Glu; E). DA; F). NE; G). 5-HT; H). citalopram; I). 
donepezil.  
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Part III 
Fig. 2. The representative chromatograms of a 1 pg/l standard mixture of neuro-
transmitters and drugs in 1:10 dilution of aCSF. A-1. ACh; B-1. DA; C-1. 5-HT; D-1. 
Histamine; E-1. NE; F-1. GABA; G-1. Glu;  H-1. Citalopram;  I-1. Donepezil. The 
representative chromatograms of 1:10 dilution of basal level microdialysates from frontal 
cortex of freely moving rat for each neurotransmitter and drug at the first hour after drug 
adminstration: A-2. ACh; B-2. DA; C-2. 5-HT; D-2. Hstamine;  E-2. NE; F-2. GABA; G-2. 
Glu; H-2. Citalopram; I-2. Donepezil. X1: the unknown molecule share the same transition 
with ACh (m/z 14687); X2:  the unknown molecule share the same transition with DA 
(m/z 154137); X3:  the unknown molecule share the same transition with 5-HT (m/z 
177160).   
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic 
use is in the treatment of Alzheimer's disease where it is used to increase cortical ACh 
release and modest benefits in cognition and/or behavior.  Therefore the extracellular ACh 
level is the efficacy biomarker for donepezil. Figure 4A shows the comparison of time course 
of donepezil and its effect on ACh efflux in frontal cortex after donepezil (2 mg/kg, s.c.) 
administration. The immediate increase in donepezil concentrations was associated directly 
with a concomitant increase in extracellular ACh levels within the first hour, which closely 
followed the fast clearance of donepezil from extracellular fluid. The donepezil 
concentration in microdialysate increased to the peak concentration, 157  23 ng/ml and 
gradually decreased to minimum concentration 5.5  0.51 ng/ml at end of experiment (18 
hours after administration). 
Citalopram is an antidepressant used to treat major depression associated with mood 
disorders. Citalopram belongs to selective serotonin reuptake inhibitors, which exert their 
therapeutic effects by increasing extracellular 5-HT level in the synaptic cleft. Figure 4B 
shows the comparison of time course of citalopram concentration and its effect on 5-HT 
efflux in frontal cortex after citalopram (10 mg/kg, s.c.) administration.  Interestingly, the 
immediate increase in citalopram concentrations was associated directly with a increase in 
extracellular 5-HT levels, however 5-HT level did not follow the fast clearance of citalopram 
from extracellular fluid and kept increasing to the peak release (545  50% of basal level) at 9 
hours after dosing, while remaining elevated for at least 18 hours. The citalopram 
concentration in microdialysate increased to the peak concentration, 281  37 ng/ml within 
1 hour of administration and was eliminated within 17 hours.  The persistent increase in 5-
HT concentrations may be related to the effect of citalopram metabolite on 5-HT release. 
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Fig. 3. Effect of donepezil (2 mg/kg, s.c., n=5 ) and citalopram (10 mg/kg, s.c., n=5) on 
extracellular concentration of neurotransmitters in the frontal cortex of rat: A. ACh; B. 
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Histamine; C. GABA; D. Glu; E. DA; F. NE and G. 5-HT. Values are mean  S.E.M.. The 
neurotransmitter levels expressed as a percentage of the average of three baseline samples 
(defined as 100%). Two ways ANOVA - post-hoc Duncan’s multiple range test were used 
for comparison. (Asterisks indicate significance of overall effect of drug treatment versus 
vehicle: * P<0.05, ** P<0.01, *** P<0.001.) 
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Fig. 4. PK/PD profiles of Donepezil and Citalopram: A. The extracellular concentration of 
donepezil and ACh in the frontal cortex of rats after Donepezil (2 mg/kg, s.c.) 
administration; B. The extracellular concentration of citalopram and 5-HT in the frontal 
cortex of rats after citalopram (10 mg/kg, s.c.) administration. Values are mean  S.E.M. The 
neurotransmitter levels was expressed as a percentage of the average of three baseline 
samples (defined as 100%) and the drug concentration was expressed as ng/ml.  
4. Discussion 
In these studies, in vivo microdialysis in conjunction with automated sampling for 24 hours 
in freely moving rats provided a very useful technique for collecting the endogenous 
neurochemicals and exogenous drugs in the specific brain region without stress from 
sampling procedures or anesthesia. Analysis of these samples with LC-MS/MS methods, 
which provide high sensitivity and structural specificity, make it possible to monitor all 
neurotransmitter release in single sample collection and is a valuable tool for evaluating 
PK/PD relationship of new chemical entities in drug discovery. 
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LC-MS/MS applications in measuring neurotransmitters in microdialysis samples were 
limited by poor retention on reversed column and high salted aCSF matrix (20). To solve the 
first problem, two novel stationary phase columns were used in this study. One column is a 
Discovery F5 column, which uses pentafluorophenyl (PEP)(22) as a function group to attach 
on the silica via a propyl chain. The PEP type phase provides greater retention of polar 
solutes without ion-pairing or ion-suppressing agents in the mobile phase. Another column 
is Primesep 200 (23), a reverse-phase analytical column with embedded weak acidic ion-
pairing groups. It improves retention of strong basic compounds by cation-exchange 
mechanism and retains neutral compounds by reverse-phase mechanism. All mobile phases 
for these two columns were LC-MS mobile phase (acetonitrile with formic acid or acetic 
acid).  ACh, DA, 5-HT, histamine, NE, GABA and Glu were retained in these columns for 2-
5 min, which is sufficient to separate them from high salt and endogenous interferences in 
microdialysis sample. The effluent that contained salts and the major ion-suppressing 
endogenous interferences were diverted to waste for the first 2-3 min as the online desalt 
step. In addition, the microdialysis sample (60 µl in each collection) was diluted to 1:10 by 
water to further reduce ion-suppressing influence from salt and endogenous interferences. 
600 µl sample volume could make several LC-MS/MS injections for monitoring different 
biomarkers or drug in different methods, since the typical LC injection volume is 10 µl. 
In contrast to the neurotransmitters, the average molecular weight of drug was 300-600 and 
drug molecule is very easy to retain on reverse phase column and separated with salt and 
ion-suppression agents.  Therefore reverse phase column was used for drug LC-MS/MS 
method. We were unable to improve the 5-HT and NE sensitivity for LC-MS/MS method to 
monitor them at a 1 to 10 dilution of microdialysate. As discussed before, they have very 
good electrochemical activity and therefore the best way to monitor 5-HT and NE is still 
HPLC-ED. 
The mass spectrometry conditions for each neurotransmitter and drug in this study are 
similar with other studies (15-19). In addition, compared with the chromatogram of 
neurotransmitter’s standard solution (as shown in Figure 2), some unknown peaks in 
microdialysis were observed by LC-MS/MS. These unknown peaks always had the same 
transition (m/z) as the neurotransmitters, as shown in Figure 2. ACh (m/z 14687) was 
eluted at 4.11 min and peak X1 (m/z 14687) was eluted at 3.24 min (Figure 2A-2). DA 
(m/z 154137) was eluted at 3.51 min and peak X2 (m/z 154137) at 3.12 min (Figure 2B-
2); 5-HT (m/z 177160) was eluted at 4.62 min and peak X3 (m/z m/z 177160) at 3.26 
min (Figure 2C-2). A similar phenomenon has been observed in a study by Zhu et al. (17). In 
their full scan MS/MS experiments, the (3-carboxypropyl) trimethylammonium was 
identified, which was the unknown peak and had the same transition as ACh (m/z 
14687).  (3-carboxypropyl) trimethylammonium has been reported to be a substrate in the 
production of -betaine hydroxylase, an enzyme in the biosynthesis of carnithine. A further 
study to identify these unknown peaks will be very interesting and may lead us to find new 
endogenous substance in the brain and expand our knowledge of neurochemistry.  
In this study, for the first time we report the effect of citalopram (and donepzile) on seven 
neurotransmitter release. In agreement with literatures, 10 mg/kg citalopram in this study 
preferentially elevated levels of 5-HT in the frontal cortex of freely moving rats (24-25). DA 
and NE were not changed by citalopram at this dose; this agrees with Millan et al.’s results 
(26). It only evoked a slight rise in levels of NE and DA even at the highest dose (40 mg/kg) 
(26). Interestingly 10 mg/kg citalopram also markedly decreased extracellular GABA 
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concentration in the frontal cortex in the same animals. To our knowledge, others have not 
reported this result, which is a favorable effect for depression patients. 10 mg/kg citalopram 
did not change the extracellular concentration of ACh, histamine and Glu in the present 
study. 
Donepezil, a potent and selective acetylcholinesterase inhibitor for the treatment of 
Alzheimer’s disease. Our results show that subcutaneous injection of donepezil (2 mg/kg) 
produced a marked (up to 7-fold) elevation of extracellular ACh in the frontal cortex. In 
previously studies, Giacobini et al. (27) examined the effect of subcutaneous injection of 
donepezil (0.5 and 2 mg/kg) on extracellular ACh concentration in the cerebral cortex of rats 
by using transcortical microdialysis. In their experimental, 2 mg/kg donepezil produced 20-
fold elevation of extracellular ACh in the cortex. It had the similar time to the maximum 
plasma concentration (1 hour after dosing) and duration (3-6 hours) (28). Our study is the 
first to report changes in extracellular Glu cortical levels in parallel with ACh after 
donepezil administration.  A similar result has been reported:  ENA713 (29), a novel 
acetylcholinesterase inhibitor, significantly decreased extracellular glutamate level in rat 
hippocampus by using in vivo microdialysis. Decreased Glu was a favorable effect for 
treatment of Alzheimer’s disease, since increased cerebrospinal fluid Glu concentration has 
been reported in Alzheimer’s disease patients (30). These applications provided a very good 
example to screen CNS drug by comparing their drug effects on multiple neurotransmitters 
release with LC-MS/MS coupled to in vivo microdialysis. The results may help us to find the 
new therapeutic indication for an old drug.  
In present study, the basal level 5-HT, NE and DA in the frontal cortex of rats which were 
measured by LC-MS/MS were 0.20  0.016 pg/l (n=6), 0.40  0.015 pg/l (n=8), 0.15  
0.008 pg/l respectively, These results are correlated with the results in our lab that 
measured by HPLC-ED: 0.10  0.06 pg/l (n=50) for 5-HT; 0.36  0.15 pg/l (n=20) for NE 
and 0.06  0.05 pg/l (n=20) for DA. Due to a different route of administration and possible 
difference in the microdialysis techniques, the basal levels of other neurotransmitters in the 
frontal cortex of rats were slightly different in our study than in others, but were in similar 
ranges.  
Since the method development of LC-MS/MS for drugs is relatively easier than for 
neurotransmitters and is amenable to a 1/10 dilution of microdialysis samples, this provides 
a unique opportunity to estimate drug CNS penetration and elucidate PK/PD profiles by 
monitoring concentrations of a drug simultaneous with drug induced neurotransmitter 
release in the same animal. In Figure 4A, administration of 2 mg/kg donepezil caused a 
rapid increase in ACh. The extracellular donepezil concentration in the frontal cortex of rats 
was associated with a concomitant increased in extracelluar ACh level and reached to the 
maximal concentration in the same time.  The time-course of denepezil induced ACh efflux, 
which represents drug’s efficacy or PD property, correlated well with the concentration 
curve of donepezil.  This result suggested that donepezil had very fast blood-brain barrier 
penetration and inhibited the ChE, which directly elevated ACh release on the site of drug 
action.  This result demonstrates good agreement with drug PK/PD properties.  
In Figure 4B, administration of 10 mg/kg citalopram caused an immediate increase of 5-HT 
in rat frontal cortex. However, the time-course of citalopram induced 5-HT efflux did not 
parallel the biophase PK profile of citalopram. This finding indicates that the time-course for 
extracellular 5-HT in the frontal cortex reflects a more complex mechanism than direct 
action of citalopram on 5-HT reuptake inhibition at its dose. Citalopram has several 
www.intechopen.com
 
Tandem Mass Spectrometry – Applications and Principles 
 
436 
metabolites, demethylcitalopram (DCIT), didemethylcitalopram (DDCIT), and citalopram 
N-oxide (CIT-NO) in human plasma and urine (31-32). Due to lack of commercial standards 
of citalopram metabolite, their concentration in microdialysate could not be measured in 
this study.  
These examples illustrate the applicability of the LC-MS/MS coupled to in vivo 
microdialysis technique to rapidly estimate the PK/PD profiles of novel substances. This 
technique will be a very useful tool to study the drug penetration of BBB in lead 
optimization of drug discovery. Compared to the traditional method for the study of drug 
BBB penetration (33), this technique avoids having to euthanize the animal at each time 
point to measure drug concentration in whole brain tissue and provides continually 
monitoring extracellular drug concentration in specific brain regions at each hour for a 24-
hour period by using a single animal as shown in table 2.  
 
 
 
  
Traditional Method 
 
In vivo microdialysis-LC/MS/MS method 
 
Specificity 
 
 Using whole brain tissue 
 
 
 Measure total (intracellular 
plus extracellular) drug 
concentration  
 
 
 Sample from individual brain 
region (such as frontal cortex, 
striatum, hippocampus, 
hypothalamus) 
 Measure extracellular drug 
concentration 
 
 
Efficiency 
 
 Using 8 animals to get 8 time 
points 
 More labor to sacrifice each 
animal, homogenate brain  
 
 Sample preparation for LC 
injection 
  
 
 Using 1 animal to get 24 time points 
 Automatic sample collection for 24 
hours without supervision. Only 
need to implant microdialysis 
probe guide by brain surgery. 
 Sample ready for LC injection 
 
 
Information 
 
 
 PK data (drug concentration 
in the brain) 
 
 
 PK and PD data (both drug and 
biomarker concentration) 
 
 
Table 2. Comparison of drug blood-brain barrier (BBB) penetration study by using 
traditional method versus in vivo microdialysis-LC/MS/MS method. 
5. Conclusion 
This study demonstrated that liquid Chromatography/tandem mass spectrometry (LC-
MS/MS) coupled with in vivo microdialysis provides a powerful method for the 
measurement of endogenous and exogenous substances in the brain interstitial fluid (ISF) 
surrounding the probe and so it represents an important tool in CNS drug discovery.  1). It 
can be used to measure the pharmacodynamic response of neuroactive compounds, 
represents the drug efficacy, by measuring neurotransmitters and other biomarkers; 2). A 
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core requirement for an effective CNS drug is an ability to cross the BBB and remain in the 
brain ISF for sufficient duration and concentration to evoke the desired therapeutic effect. 
LC-MS/MS coupled with in vivo microdialysis can be used to evaluate the BBB penetration 
of drug candidate by measuring the free concentration of CNS drug in brain ISF; 3). The 
profile of time-free concentration of CNS drug in the targeted brain region provides 
biophase pharmacokinetic information which can differ significantly from 
pharmacokinetics in plasma. Establishing PK-PD relationship of the drug, especially 
biophase PK, allow better understanding of exposure-response relationships and help the 
selection of drug; 4). In some case, not parent drug, but drug metabolite contributes to 
efficacy or toxicity. LC-MS/MS coupled with in vivo microdialysis also can be used to study 
drug metabolism during drug discovery.    
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